• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Keytruda combo wins FDA approval for RCC pharmatimes
    April 25, 2019
    The US Food and Drug Administration (FDA) has approved MSD’s Keytruda (pembrolizumab), in combination with Inlyta(axitinib), as first-line treatment for patients with advanced renal cell carcinoma (RCC).
  • Keytruda combo set to become “standard of care” in kidney cancer pharmaphorum
    February 19, 2019
    Analysts are predicting that a combination of Merck’s Keytruda and Pfizer’s Inlyta will become the standard of care in renal cell carcinoma (RCC) thanks to impressive trial results and a price advantage over BMS’ rival drug.....

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service